HepaVue
Revolutionizing Liver Diagnostics with First-in-Class Virtual Biopsy

In a nutshell
Over 2 billion people – more than a quarter of the world population – suffer from chronic liver disease. Today, the needle biopsy remains the only diagnostic option. This method is fraught with disadvantages. It is expensive, painful, resource-intensive, samples only a tiny part of the liver and carries a bleeding/mortality risk. As such it is unsuitable for mass screening. This shortcoming - coupled with liver diseases progressing silently - results in 70% of patients going unnoticed until terminal stage (cirrhosis). HepaVue has developed the world’s first virtual liver biopsy which will make liver disease diagnosis affordable, painless, safe and more accessible. Our technology will prevent avoidable cases of liver cancer, transplantations and deaths.

Why is our technology important?
HepaVue combines molecular tracers and AI-based medical imaging technology to offer accurate and early detection of progressive liver diseases. This first-in-class solution replaces traditional invasive biopsies, offering a safer, more cost-effective approach that supports widespread screening among high-risk individuals. By detecting signs of progressive liver disease early on, we enable immediate management strategies – potentially saving millions of lives in the process.

The benefits of our solution
❖ Enhanced patient care: Eliminates the need for painful and invasive biopsies, reducing patient discomfort and risk of life-threatening complications from this procedure
❖ Early detection: By identifying liver disease earlier, HepaVue provides a critical window for impactful therapeutic interventions, enhancing the chances of recovery
❖ Precision medicine: By offering a holistic analysis of liver and metabolic health, we empower healthcare providers to tailor medical interventions
❖ Cost-effective mass screening: Lower financial barrier to diagnosis, making widespread proactive screening feasible

HepaVue is not just developing a technology; we are leading a transformation in liver health management. Through timely and proactive care, we will drastically reduce the prevalence of terminal liver diseases, moving us closer to a world where it is an exception rather than a common fate.

Keywords
Biotech – Diagnostics – Liver – Molecular Imaging - Artificial Intelligence – Screening – Precision medicine

Founding Team
Maxime Nachit, CEO & Co-founder
Gaby El Alam, Co-founder

Get in touch
We’d love to speak to you more about our project.
You can book some time with us here: maxime.nachit@gmail.com